You can help expand this article with text translated from the corresponding article in Spanish. (December 2021)Click [show] for important translation instructions.
|
Date | 9 February 2021 |
---|---|
Location | Peru |
Cause | COVID-19 pandemic in Peru |
Target | Immunisation of Peruvians against COVID-19 |
Organised by | Ministry of Health of Peru |
Website | Gobierno del Perú |
The COVID-19 vaccination program in Peru is the national vaccination strategy to protect the population against SARS-CoV-2 employing vaccines developed for the COVID-19 pandemic in Peru. Vaccination began on 9 February 2021, after three days of arrival of first vaccines. [1] On a nation message, the head of state Francisco Sagasti confirmed the purchase of 38 millions of vaccines, being one million of vaccines for health personnel. [2]
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
On 7 February 2021 at 19:54 h (UTC−5), 300,000 vaccines lot of Sinopharm coming from China arrived at the airport Jorge Chávez. [3] This event was overseen by the president, Francisco Sagasti. Shortly after, the head of state reported that on 14 February a remaining lot 700,000 vaccines will also arrive to the country. [4] On 8 February 2021, a thousand police officers were reported to guard the warehouse of National Center for the Supply of Strategic Health Resources (CENARES, acronym in Spanish). [5]
According to the Government of Peru, the vaccination is predicted in three phases. [6]
Stage | People included |
---|---|
1 |
|
2 |
|
3 |
|
According to the study presented by IPSOS, a French sociological and market research company, the acceptance of the vaccine in the Peruvian population was below 50% until January 2021 due to an environment of mistrust in the management of the Vaccination and management of the pandemic during the government of Martín Vizcarra and Francisco Sagasti. As of February 2021, the period that begins the vaccination process, the study revealed a slow and steady increase in the acceptance of the COVID-19 vaccine.[ citation needed ]
Option Month | I do want to get vaccinated | I don't want to get vaccinated | I already got vaccinated | Not precise | Source |
---|---|---|---|---|---|
Aug 2020* | 75% | 22% | 0% | 3% | [7] |
Dec 2020* | 57% | 40% | 0% | 3% | [8] |
Jan 2021* | 48% | 48% | 0% | 4% | [9] |
Feb 2021* | 59% | 35% | 0% | 6% | [10] |
Mar 2021** | 60% | 33% | 0% | 7% | [11] |
May 2021* | 63% | 30% | 4% | 3% | [12] |
Note: (*) It was asked how "If right now a vaccine approved by the Ministry of Health and free to prevent the COVID-19, do you? would you be vaccinated or not vaccinated?
Note 2: (**) He wondered how "If tomorrow it's your turn for the COVID-19 vaccine, would you or would you not get the vaccine?"
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
Vaccine name | Doses | Progress | Quantity [13] | Approval | Deployment | Last delivery |
---|---|---|---|---|---|---|
Sinopharm BIBP | Two | Phase III clinical trials | 6 million | 6 January 2021 [14] | 7 February 2021 [15] | 5 June 2021 |
Pfizer–BioNTech | Two | Phase III clinical trials | 20,5 million | 9 February 2021 [16] [17] | 3 March 2021 [18] | 1 July 2021 |
12 million | 6 May 2021 [19] | |||||
35 million | 17 September 2021 [20] [21] | |||||
Oxford–AstraZeneca and Pfizer–BioNTech (by Covax Facility) | Two | Phase III clinical trials | 13,2 million | 18 September 2020 [22] [23] | 10 March 2021 [24] | 3 June 2021 |
Oxford–AstraZeneca | Two | Phase III clinical trials | 14 million | 6 January 2021 [25] | Not yet | Not yet |
Johnson & Johnson | One | Phase III clinical trials | Pending | 8 July 2021 [26] | Not yet | Not yet |
Sputnik V | Two | Phase III clinical trials | 20 million | 20 July 2021 [27] | Not yet | Not yet |
Moderna | Two | Phase III clinical trials | 20 million | 17 September 2021 [28] | Not yet | Not yet |
Chronology of the doses arrived in Peru | ||||
---|---|---|---|---|
No. | Vaccine name | Quantity | Arrival date | Source(s) |
1 | Sinopharm BIBP | 300,000 | 7 February 2021 | [15] |
2 | Sinopharm BIBP | 700,000 | 13 February 2021 | [29] |
3 | Pfizer–BioNTech | 50,000 | 3 March 2021 | [18] |
4 | Pfizer–BioNTech (by Covax Facility) | 117,000 | 10 March 2021 | [24] |
5 | Pfizer–BioNTech | 50,000 | 10 March 2021 | [24] [30] |
6 | Pfizer–BioNTech | 50,000 | 17 March 2021 | [31] |
7 | Pfizer–BioNTech | 50,310 | 24 March 2021 | [32] |
8 | Pfizer–BioNTech | 49,140 | 31 March 2021 | [33] |
9 | Pfizer–BioNTech | 200,070 | 7 April 2021 | [34] |
10 | Pfizer–BioNTech | 200,700 | 14 April 2021 | [35] |
11 | Oxford-AstraZeneca (by Covax Facility) | 276,000 | 18 April 2021 | [36] |
12 | Pfizer–BioNTech | 200,700 | 21 April 2021 | [37] |
13 | Pfizer–BioNTech | 200,000 | 28 April 2021 | [38] |
14 | Pfizer–BioNTech | 350,000 | 6 May 2021 | [39] |
15 | Pfizer–BioNTech | 350,000 | 7 May 2021 | [40] |
16 | Pfizer–BioNTech | 700,000 | 13 May 2021 | [17] |
17 | Pfizer–BioNTech | 395,000 | 17 May 2021 | [41] |
18 | Pfizer–BioNTech | 395,000 | 20 May 2021 | [42] |
19 | Pfizer–BioNTech | 396,630 | 24 May 2021 | [43] |
20 | Pfizer–BioNTech | 395,460 | 26 May 2021 | [44] |
21 | Oxford-AstraZeneca (by Covax Facility) | 511,200 | 29 May 2021 | [45] |
22 | Pfizer–BioNTech | 251,550 | 31 May 2021 | [46] |
23 | Sinopharm BIBP | 700,000 | 2 June 2021 | [47] |
24 | Pfizer–BioNTech (by Covax Facility) | 468,000 | 3 June 2021 | [48] |
25 | Pfizer–BioNTech | 250,380 | 3 June 2021 | [48] |
26 | Pfizer–BioNTech | 242,190 | 4 June 2021 | [49] |
27 | Sinopharm BIBP | 300,000 | 5 June 2021 | [50] |
28 | Pfizer–BioNTech | 496,080 | 10 June 2021 | [51] |
29 | Pfizer–BioNTech | 497,250 | 17 June 2021 | [52] |
30 | Pfizer–BioNTech | 497,250 | 24 June 2021 | [53] |
31 | Pfizer–BioNTech (United States donation) | 1,002,000 | 29 June 2021 | [54] |
32 | Pfizer–BioNTech | 497,250 | 1 July 2021 | [55] |
33 | Pfizer–BioNTech (United States donation) | 998,000 | 7 July 2021 | [56] |
34 | Sinopharm BIBP | 614,400 | 10 July 2021 | [57] |
35 | Sinopharm BIBP | 385,600 | 11 July 2021 | [58] |
36 | Pfizer–BioNTech | 281,970 | 15 July 2021 | [59] |
37 | Pfizer–BioNTech | 886,860 | 22 July 2021 | [60] |
38 | Pfizer–BioNTech | 936,000 | 26 July 2021 | [61] |
39 | Pfizer–BioNTech | 196,560 | 30 July 2021 | [62] |
40 | Sinopharm BIBP | 1,000,000 | 1 August 2021 | [63] |
41 | Oxford–AstraZeneca (Spain donation) | 101,760 | 4 August 2021 | [64] |
42 | Pfizer–BioNTech | 475,020 | 5 August 2021 | [65] |
43 | Pfizer–BioNTech | 569,790 | 12 August 2021 | [66] |
44 | Sinopharm BIBP | 1,000,000 | 15 August 2021 | [67] |
45 | Pfizer–BioNTech | 594,360 | 20 August 2021 | [68] |
46 | Sinopharm BIBP | 614,400 | 21 August 2021 | [69] |
47 | Sinopharm BIBP | 385,600 | 22 August 2021 | [70] |
48 | Pfizer–BioNTech | 540,540 | 26 August 2021 | [71] |
49 | Sinopharm BIBP | 1,000,000 | 29 August 2021 | [72] |
50 | Oxford–AstraZeneca (Canada donation) | 35,100 | 2 September 2021 | [73] |
51 | Pfizer–BioNTech | 662,220 | 3 September 2021 | [74] |
52 | Sinopharm BIBP | 2,000,000 | 4 September 2021 | [75] |
53 | Pfizer–BioNTech | 748,800 | 6 September 2021 | [76] |
54 | Oxford–AstraZeneca (by Covax Facility) | 362,400 | 8 September 2021 | [77] |
55 | Sinopharm BIBP | 2,862,500 | 10 September 2021 | [78] |
56 | Sinopharm BIBP | 3,342,600 | 11 September 2021 | [79] |
57 | Sinopharm BIBP | 794,900 | 12 September 2021 | [80] |
58 | Pfizer–BioNTech | 748,800 | 13 September 2021 | [81] |
59 | Oxford–AstraZeneca (Ecuador donation) | 336,000 | 13 September 2021 | [82] |
60 | Oxford–AstraZeneca (by Covax Facility) | 146,400 | 14 September 2021 | [83] |
Dose count and statistics | ||||||||
---|---|---|---|---|---|---|---|---|
Vaccine name | Quantity | Total | % of population | Target population [84] [85] | % of population | Population (est. 2020) [86] | ||
One dose | Two dose | One dose | Two dose | |||||
Sinopharm BIBP | 16,000,000 | 33,761,600 | 123.92% | 61.96% | 27,244,203 | 103.48% | 51.74% | 32,625,948 |
Pfizer-BioNTech | 15,992,740 | |||||||
Oxford-AstraZeneca | 1,768,860 |
Vaccine | Type (technology) | Phase I | Phase II | Phase III |
---|---|---|---|---|
Sinopharm BIBP | Inactivated | Completed | Completed | Completed |
Pfizer–BioNTech | RNA | Completed | Completed | Completed |
Oxford–AstraZeneca | Viral vector | Completed | Completed | Completed |
Janssen | Viral vector | Completed | Completed | In progress |
CureVac | RNA | Completed | Completed | In progress |
Department and autonomous province | First dose | Second dose | Cumulative dose | Population (est. 2020) [86] | ||
---|---|---|---|---|---|---|
Total | % of pop. | Total | % of pop. | |||
Peru | 12,391,748 | 37.98% | 8,933,405 | 27.38% | 21,325,153 | 32,625,948 |
Amazonas | 136,284 | 31.93% | 87,684 | 20.54% | 223,968 | 426,806 |
Ancash | 462,904 | 39.21% | 335,213 | 28.39% | 798,117 | 1,180,638 |
Apurimac | 173,013 | 40.17% | 109,310 | 25.38% | 282,323 | 430,736 |
Arequipa | 631,543 | 42.17% | 461,804 | 30.84% | 1,093,347 | 1,497,438 |
Ayacucho | 213,214 | 31.91% | 132,005 | 19.75% | 345,219 | 668,213 |
Cajamarca | 476,824 | 32.80% | 318,320 | 21.90% | 795,144 | 1,453,711 |
Callao province | 579,182 | 51.26% | 435,523 | 38.55% | 1,014,705 | 1,129,854 |
Cusco | 444,355 | 32.74% | 333,979 | 24.61% | 778,334 | 1,357,075 |
Huancavelica | 127,322 | 34.85% | 94,532 | 25.88% | 221,854 | 365,317 |
Huanuco | 206,599 | 27.17% | 128,563 | 16.91% | 335,162 | 760,267 |
Ica | 400,451 | 41.06% | 265,235 | 27.20% | 665,686 | 975,182 |
Junin | 508,964 | 37.38% | 397,651 | 29.21% | 906,615 | 1,361,467 |
La Libertad | 661,806 | 32.82% | 443,839 | 22.01% | 1,105,645 | 2,016,771 |
Lambayeque | 386,439 | 29.48% | 277,086 | 21.14% | 663,525 | 1,310,785 |
Lima | 444,891 | 46.65% | 295,779 | 31.01% | 740,670 | 953,715 |
Lima province | 4,456,211 | 46.06% | 3,425,830 | 35.41% | 7,882,041 | 9,674,755 |
Loreto | 215,317 | 20.95% | 147,365 | 14.34% | 362,682 | 1,027,559 |
Madre de Dios | 40,197 | 23.13% | 26,153 | 15.05% | 66,350 | 173,811 |
Moquegua | 80,252 | 41.64% | 61,156 | 31.73% | 141,408 | 192,740 |
Pasco | 112,817 | 41.49% | 81,992 | 30.15% | 194,809 | 271,904 |
Piura | 625,908 | 30.56% | 422,917 | 20.65% | 1,048,825 | 2,047,954 |
Puno | 274,952 | 22.21% | 150,940 | 12.19% | 425,892 | 1,237,997 |
San Martin | 281,842 | 31.33% | 189,418 | 21.05% | 471,260 | 899,648 |
Tacna | 198,557 | 53.52% | 147,786 | 39.84% | 346,343 | 370,974 |
Tumbes | 93,790 | 37.29% | 58,474 | 23.25% | 152,264 | 251,521 |
Ucayali | 158,114 | 26.84% | 104,851 | 17.80% | 262,965 | 589,110 |
COVID-19 vaccination progress in Peru [87] Estimated population to be vaccinated: 27,244,203 people [88] [85]
(Inoculated with first dose)
(Inoculated with second dose) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Date | First dose | Second dose | Cumulative dose | ||||||||||||
Total | Variation | % of pop. | Total | Variation | % of pop. | ||||||||||
9-feb-21 | 3,842 | 3,842 | 0.01% | 0 | 0 | 0.00% | 3,842 | ||||||||
15-feb-21 | 110,792 | 106,950 | 0.41% | 0 | 0 | 0.00% | 110,792 | ||||||||
1-mar-21 | 321,851 | 211,059 | 1.18% | 0 | 0 | 0.00% | 321,851 | ||||||||
15-mar-21 | 430,874 | 109,023 | 1.58% | 173,578 | 173,578 | 0.64% | 604,452 | ||||||||
1-apr-21 | 662,463 | 231,589 | 2.43% | 377,945 | 204,367 | 1.39% | 1,040,408 | ||||||||
15-abr-21 | 743,077 | 80,614 | 2.73% | 544,887 | 166,942 | 2.00% | 1,287,964 | ||||||||
1-may-21 | 1,127,587 | 384,510 | 4.14% | 687,606 | 142,719 | 2.52% | 1,815,193 | ||||||||
15-may-21 | 1,815,080 | 687,493 | 6.66% | 825,828 | 138,222 | 3.03% | 2,640,908 | ||||||||
1-jun-21 | 2,984,620 | 1,169,540 | 10.96% | 1,332,284 | 506,456 | 4.89% | 4,316,904 | ||||||||
15-jun-21 | 3,829,456 | 844,836 | 14.06% | 2,236,998 | 904,714 | 8.21% | 6,066,454 | ||||||||
1-Jul-21 | 4,612,161 | 782,705 | 16.93% | 3,287,742 | 1,050,744 | 12.07% | 7,899,903 | ||||||||
15-jul-21 | 6,474,729 | 1,862,568 | 23.77% | 3,845,047 | 557,305 | 14.11% | 10,319,776 | ||||||||
1-aug-21 | 8,035,796 | 1,561,067 | 29.50% | 5,287,167 | 1,442,120 | 19.41% | 13,322,963 | ||||||||
15-aug-21 | 9,215,626 | 1,023,435 | 33.83% | 6,920,113 | 1,437,778 | 25.40% | 16,135,739 | ||||||||
1-sep-21 | 10,519,572 | 1,184,432 | 38.61% | 8,314,606 | 1,191,212 | 30.52% | 18,834,178 | ||||||||
15-sep-21 | 12,391,748 | 1,747,180 | 45.48% | 8,933,405 | 495,538 | 32.79% | 21,325,153 |
Year group | Male | Female | First dose | Second dose | Cumulative dose | Population (est. 2020) [90] | ||||
---|---|---|---|---|---|---|---|---|---|---|
One dose | Two dose | One dose | Two dose | Total | % of pop. | Total | % of pop. | |||
Total | 5,883,925 | 4,205,383 | 6,507,830 | 4,728,027 | 12,391,755 | 37.98% | 8,933,410 | 27.38% | 21,325,165 | 32,625,948 |
0-9 | 0 | 0 | 0 | 0 | 0 | 0.00% | 0 | 0.00% | 0 | 5,384,070 |
10-19 | 1 | 2 | 1 | 2 | 2 | 0.00% | 4 | 0.00% | 6 | 5,206,372 |
20-29 | 268,104 | 165,164 | 276,265 | 147,666 | 544,369 | 10.07% | 312,830 | 5.79% | 857,199 | 5,403,670 |
30-39 | 902,481 | 227,252 | 1,048,431 | 295,265 | 1,950,912 | 38.78% | 522,517 | 10.39% | 2,473,429 | 5,031,117 |
40-49 | 1,469,356 | 916,504 | 1,618,837 | 1,057,378 | 3,088,193 | 73.82% | 1,973,882 | 47.19% | 5,062,075 | 4,183,147 |
50-59 | 1,323,836 | 1,122,048 | 1,433,083 | 1,243,231 | 2,756,919 | 84.13% | 2,365,279 | 72.18% | 5,122,198 | 3,277,134 |
60-69 | 991,384 | 906,676 | 1,065,272 | 983,839 | 2,056,656 | 92.59% | 1,890,515 | 85.11% | 3,947,171 | 2,221,241 |
70-79 | 598,883 | 560,388 | 653,300 | 614,198 | 1,252,183 | 98.45% | 1,174,586 | 92.35% | 2,426,769 | 1,271,842 |
80+ | 329,878 | 307,348 | 412,638 | 386,448 | 742,516 | 114.70% | 693,796 | 107.17% | 1,436,312 | 647,355 |
No data | 2 | 1 | 3 | 0 | 5 | - | 1 | - | 6 | - |
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
Data source: Platform of "Datos abiertos", Government of Peru. [89]
Percentage of population (2020) with second dose in most populated provinces of the country.
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
Note: Name of provinces and department name in parentheses. Chiclayo (Lambayeque), Coronel Portillo (Ucayali), Huancayo (Junin), Lima (Lima province), Maynas (Loreto), Santa (Ancash) and Trujillo (La Libertad)
Data source: Platform of "Datos abiertos", Government of Peru. [89]
Districts of the city of Lima with the highest reception of people who were inoculated with the two doses with respect to the size of their population (est. 2020). The districts with the highest percentage vaccinate people who come from other districts and have large vaccination centers.
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
Data source: Platform of "Datos abiertos", Government of Peru. [89]
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
Data source: Platform of "Datos abiertos", Government of Peru. [89]
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
Data source: Platform of "Datos abiertos", Government of Peru. [89]
Pilar Elena Mazzetti Soler is a Peruvian physician and health administrator who served as Minister of Health from July 2020 to February 2021, excluding her for nine days from office during the brief presidency of Manuel Merino. She previously held the position from February 2004 to July 2006, and was briefly Minister of the Interior from July 2006 to February 2007, being the first woman to reach said position in the Peruvian government.
Óscar Raúl Ugarte Ubilluz is a Peruvian physician who is the current Minister of Health under President Francisco Sagasti since 13 February 2021. He previously held the position under President Alan García from October 2008 to July 2011.
Martín Alberto Vizcarra Cornejo is a Peruvian engineer and politician who served as President of Peru from 2018 to 2020. Vizcarra previously served as Governor of the Department of Moquegua (2011–2014), First Vice President of Peru (2016–2018), Minister of Transport and Communications of Peru (2016–2017), and Ambassador of Peru to Canada (2017–2018), with the latter three during the presidency of Pedro Pablo Kuczynski.
Chinchero International Airport is an under construction international airport in the town of Chinchero, which is located in the district of the same name, in Cusco Region, Perú. It is planned to replace Alejandro Velasco Astete International Airport. Its altitude is 3,720 metres (12,200 ft) above sea level.
Vicente Antonio Zeballos Salinas is a Peruvian politician who served as Prime Minister of Peru from September 2019 to July 2020, under President Martín Vizcarra's administration. Prior, he served as Minister of Justice and Human Rights.
The COVID-19 pandemic in Peru has resulted in 4,524,748 confirmed cases of COVID-19 and 220,831 deaths. The virus spread to Peru on 6 March 2020, when a 25-year-old man who had travelled to Spain, France, and the Czech Republic tested positive. On 15 March 2020, President Martín Vizcarra announced a country-wide lockdown, closing borders, restricting domestic flights, and forbidding nonessential business operations, excluding health facilities, grocery stores, pharmacies, and banks. As of May 2023, Peru has the highest COVID-19 death rate in the world, with over 6,400 deaths per one million citizens.
The COVID-19 pandemic in Uruguay has resulted in 1,037,893 confirmed cases of COVID-19 and 7,625 deaths.
Manuel Arturo Merino de Lama is a Peruvian politician who briefly served as President of Peru for six days between 10 and 15 November 2020. He also served as the President of Congress from 16 March 2020 to 15 November 2020. He was a Member of Congress (AP) representing the Tumbes constituency for the 2001–2006, 2011–2016, and 2020–2021 terms.
Together for Peru is a Peruvian centre-left to left-wing political coalition founded with the incumbent registration of the Peruvian Humanist Party.
Carolina Lizárraga Houghton is a Peruvian lawyer, jurist, and politician who serves as a member of the Congress of the Republic of Peru (PM), representing the Lima constituency.
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, the Sinopharm COVID-19 vaccine, or BIBP vaccine, is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants. BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19. Its product name is SARS-CoV-2 Vaccine, not to be confused with the similar product name of CoronaVac.
Events in the year 2021 in Uruguay.
Soberana 02 or Soberana 2, technical name FINLAY-FR-2, is a COVID-19 vaccine produced by the Finlay Institute, a Cuban epidemiological research institute. The vaccine is known as PastoCovac in Iran, where it has been developed in collaboration with the Pasteur Institute of Iran.
The COVID-19 vaccination program in Colombia is an ongoing effort of mass immunization put in place by the Colombian government in order to respond to the ongoing COVID-19 pandemic. The virus causing COVID-19 was confirmed to have reached Colombia on 6 March 2020. Colombia's preparation and readiness for a vaccine program allowed it to join the first group of countries who received vaccines through COVAX. The first vaccine in Colombia was given to a nurse on 17 February 2021.
The COVID-19 pandemic in Cuzco is part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2. The virus was reported to have spread to Cusco on 13 March 2020, when a 37-year-old man who had travelled to United States tested positive. The start of the epidemic outbreak in The country, also called "community transmission", was announced on March 17, 2020, while the first death was reported a week later. As time passed, the outbreak spread throughout the department, Paruro being the last province to report its first positive case on May 6, 2020. In the district of Villa Virgen, La Convención Province, a first positive case of contagion by COVID-19 was confirmed on August 24, 2020, becoming the last district of the department to declare the presence of infected persons. The exponential increase in infections, which occurred since the third week of July, positioned Cuzco as the third department with the most cases in Peru.
Vacunagate refers to a scandal in Peru over the secret COVID-19 vaccination of 487 people, mainly senior officials of the Executive Power of Peru. The crisis began on February 10, 2021, with the revelation that in October 2020 a coronavirus vaccine intended for Phase III of the Sinopharm clinical trials was secretly given to then-President Martín Vizcarra.
COVID-19 vaccination in Mexico is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
The COVID-19 vaccination program in Argentina is an ongoing effort of mass immunization. Vaccination against COVID-19 began in Argentina on 29 December 2020 aiming at health professionals. Argentina struck a deal with the United Kingdom in November 2020 for a British made vaccine produced by the pharmaceutical company AstraZeneca and the University of Oxford. The vaccines are part of a deal where Argentina received 22.4 million doses. During the first week, 39,599 doses were applied to health professionals.
César Rodrigo Landa Arroyo is a Peruvian professor and politician. He served as Minister of Foreign Relations of Peru intermittently from February to December 2022 under the presidency of Pedro Castillo. He also served as president of the Constitutional Court of Peru between 2006 and 2008, and vice minister of Justice in 2004.